Immunogenicity of a CpG-adjuvanted recombinant plague vaccine

Inventors

JANSSEN, Robert S. • NOVACK, David • Chung, Wai Kwan • Glenn, Andrew M. • WARD, Lucy A.

Assignees

Dynavax Technologies Corp • United States Department of the Army

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12364745-B2

Patent

Publication Date

2025-07-22

Expiration Date


Abstract

The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.

Core Innovation

The invention describes an immunogenic composition combining an unmethylated CpG-containing oligonucleotide, at least one Yersinia pestis antigen, and an aluminum salt adjuvant. The partial content identifies recombinant F1V fusion protein as an antigen form and describes the composition as a plague vaccine. The claimed presentations also include a vial and a pre-filled syringe containing the composition.

The partial content reports interim Phase II findings of higher anti-rF1V antibody geometric mean concentrations when CpG is used with rF1V than with rF1V alone, with the strongest reported response following bedside mixing. It describes a two-dose CpG-adjuvanted regimen as a potential alternative to a longer schedule; the clinical trial is ongoing. The background section is not included, so the problem being solved is not explicitly described.

Claims Coverage

The partial content identifies five independent claims covering an immunogenic composition, two product presentations, and two kit configurations.

Immunogenic composition

A composition comprising an unmethylated CpG-containing oligonucleotide, at least one Yersinia pestis antigen, and an aluminum salt adjuvant.

Vial containing the immunogenic composition

A vial comprising an immunogenic composition containing an unmethylated CpG-containing oligonucleotide, at least one Yersinia pestis antigen, and an aluminum salt adjuvant.

Pre-filled syringe containing the immunogenic composition

A pre-filled syringe comprising an immunogenic composition containing an unmethylated CpG-containing oligonucleotide, at least one Yersinia pestis antigen, and an aluminum salt adjuvant.

Kit for preparing the immunogenic composition

A kit comprising a first composition containing an unmethylated CpG-containing oligonucleotide, a second composition containing a Yersinia pestis antigen and an aluminum salt adjuvant, and instructions for combining the compositions.

Kit for separate administration

A kit comprising a first composition containing an unmethylated CpG-containing oligonucleotide, a second composition containing a Yersinia pestis antigen and an aluminum salt adjuvant, and instructions for separate administration to stimulate an immune response against Yersinia pestis.

Together, the independent claims cover the composition and its vial and pre-filled syringe presentations, as well as kits for combining the components or administering them separately.

Stated Advantages

The interim Phase II data report higher anti-rF1V antibody geometric mean concentrations with CpG than with rF1V alone; bedside mixing produces the strongest reported response.

The reported findings support a two-dose CpG-adjuvanted regimen as a potential alternative to a longer schedule.

Documented Applications

The immunogenic composition is described as a plague vaccine for stimulating an immune response against Yersinia pestis.

The kit configurations are described for preparing the immunogenic composition by combining its components or for their separate administration.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.